Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Report: Biden to buy 100M additional doses of J&J COVID-19 vaccine

By Sean Whooley | March 10, 2021

Johnson & JohnsonPresident Joe Biden is reportedly set to announce plans to purchase an additional 100 million doses of Johnson & Johnson’s (NYSE:JNJ) COVID-19 vaccine.

An NBC News report said that Biden is set to announce the purchase of the single-dose vaccines on Wednesday, according to two officials from his administration.

The purchase of doses from Johnson & Johnson, which became the third authorized COVID-19 vaccine in the U.S. last month (and the first single-dose vaccine), puts the U.S. in a position in which it has more than enough supply to vaccinate the entire population of the country. This comes after Biden recently pushed forward the timeline for having enough doses to vaccinate every American, moving it from the end of July to the end of May.

Biden is reportedly set to direct the U.S. Dept. of Health & Human Services to procure the doses during a meeting with executives from J&J and Merck, having announced earlier this month that the two pharmaceutical competitors were teaming up to produce the vaccines.

Last month, the government finalized a deal with Pfizer and Moderna, the other two developers of authorized vaccines, for 200 million more doses, which would already give the U.S.enough doses for every adult even before J&J’s vaccine was greenlighted, once produced. The agreement for another 100 million doses from J&J offers more flexibility, both with the single-dose option and in the event that Pfizer or Moderna hit production snags.


Filed Under: Drug Delivery, Drug Discovery, Drug Discovery and Development, Infectious Disease
Tagged With: coronavirus, covid-19, COVID-19 vaccine, Johnson & Johnson
 

About The Author

Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Related Articles Read More >

A display of DNA sequencing output from an automated ABI 373 sequencer. [National Human Genome Research Institute (NHGRI)]
Helix and Recursion join forces in quest to crack the AI-driven drug discovery code
Ypsomed Ypsodose patch injector
ten23 health to develop large-volume injectables for Ypsomed’s YpsoDose
Shasqi
Click chemistry breakthroughs drive Shasqi and J&J cancer alliance
Shasqi
Nobel-connected startup Shasqi deepens J&J partnership on CAPAC platform
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE